Literature DB >> 7535817

Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum.

U Blum-Tirouvanziam1, C Servis, A Habluetzel, D Valmori, Y Men, F Esposito, L Del Nero, N Holmes, N Fasel, G Corradin.   

Abstract

Localization of human MHC class I-restricted T cell epitopes in the circumsporozoite (CS) protein of the human parasite Plasmodium falciparum is an important objective in the development of antimalarial vaccines. To this purpose, we synthesized a series of overlapping synthetic 20-mer peptides, spanning the entire sequence of the 7G8 CS molecule except for the central repeat B cell domain. The P.f.CS peptides were first tested for their ability to bind to the human MHC class I HLA-A2.1 molecule on T2, a human cell line. Subsequently, the use of a series of shorter peptide analogues allowed us to determine the optimal A2.1 binding sequence present in several of the 20-mers. Binding P.f.CS peptides were further tested for their capacity to activate PBL from HLA-A2.1+ immune donors living in a malaria-endemic area. Specific IFN-gamma production was detected in the supernatant of cultures of PBL from exposed individuals. Cytotoxic T cell lines and clones were derived from the PBL of one responder, and their activity was shown to be HLA-A2.1-restricted and specific for the peptide 334-342 of the CS protein. In addition, double transgenic HLA-A2.1 x human beta 2-microglobulin mice were immunized with peptide 1-10 of the CS protein. T cells derived from immune lymph nodes displayed a peptide-specific HLA-A2.1-restricted cytolytic activity after one in vitro stimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535817

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Apoptosis and the balance of homeostatic and pathologic responses to protozoan infection.

Authors:  L Cristina Gavrilescu; Eric Y Denkers
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

2.  HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls.

Authors:  Kirsten E Lyke; Robin B Burges; Yacouba Cissoko; Lansana Sangare; Abdoulaye Kone; Modibo Dao; Issa Diarra; Marcelo A Fernández-Vina; Christopher V Plowe; Ogobara K Doumbo; Marcelo B Sztein
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.

Authors:  Ania Skowera; Richard J Ellis; Ruben Varela-Calviño; Sefina Arif; Guo Cai Huang; Cassie Van-Krinks; Anna Zaremba; Chloe Rackham; Jennifer S Allen; Timothy I M Tree; Min Zhao; Colin M Dayan; Andrew K Sewell; Wendy W Unger; Wendy Unger; Jan W Drijfhout; Ferry Ossendorp; Bart O Roep; Mark Peakman
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 4.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 5.  Transgenic models of autoimmune disease.

Authors:  R J Boyton; D M Altmann
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

6.  A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice.

Authors:  Xiangming Li; Jing Huang; Izumi Kaneko; Min Zhang; Shiroh Iwanaga; Masao Yuda; Moriya Tsuji
Journal:  Expert Rev Vaccines       Date:  2016-11-16       Impact factor: 5.217

7.  Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3.

Authors:  M Aidoo; A Lalvani; S C Gilbert; J T Hu; P Daubersies; N Hurt; H C Whittle; P Druihle; A V Hill
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

8.  Multiple antigen peptide vaccines against Plasmodium falciparum malaria.

Authors:  Babita Mahajan; Jay A Berzofsky; Robert A Boykins; Victoria Majam; Hong Zheng; Rana Chattopadhyay; Patricia de la Vega; J Kathleen Moch; J David Haynes; Igor M Belyakov; Hira L Nakhasi; Sanjai Kumar
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

9.  Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.

Authors:  Craig L Slingluff; Galina V Yamshchikov; Kevin T Hogan; Sarah C Hibbitts; Gina R Petroni; Eric A Bissonette; James W Patterson; Patrice Y Neese; William W Grosh; Kimberly A Chianese-Bullock; Andrea Czarkowski; Patrice K Rehm; Jayashree Parekh
Journal:  Ann Surg Oncol       Date:  2008-10-16       Impact factor: 5.344

10.  The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Authors:  Régine Audran; Floriana Lurati-Ruiz; Blaise Genton; Hildur E Blythman; Opokua Ofori-Anyinam; Christophe Reymond; Giampietro Corradin; François Spertini
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.